E. DavidCrawfordMD

Urology • Aurora, CO

Surgical Oncology, Clinical Informatics

Professor of Urology, Department of Urology, University of California San Diego , CA

Join to view full profile

Dr. Crawford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Crawford's full profile

Already have an account?

Office
12605 E 16th Ave
Univ CO Hosp, Anschutz Canc Pav, Ste 1004, MS F710
Aurora, CO 80045
Phone+1 720-848-0000
Is this information wrong?

Summary

I am a board-certified urologist who has devoted my career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States.
I am an internationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer.
As a professor in the Department of Urology, I instruct medical students, residents and fellows at UC San Diego School of Medicine. I have conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. I have authored or coauthored over 810 scientific articles, published seven textbooks, authored over 60 book chapters and provided more than 2,200 educational talks for patients and physicians. I serve as editor in chief of Grand Rounds in Urology since June of 2019.
In an effort to raise public awareness about prostate health, Ifounded the Prostate Conditions Education Council (PCEC) in 1989. The non-profit organization is comprised of a consortium of leading physicians, health educators, scientists and men's health advocates. PCEC's advocacy for free or low-cost prostate screening has affected the lives of millions of American men. I currently chair the PCEC.

Consistently recognized as one of the Best Doctors of America for the past two decades, I was ranked as one of the top 20 urologists in the country by Men’s Health Magazine. In May of 2019, I received the presidential citation from the American Urological Association in recognition of his “tireless role in genitourinary cancer research that has benefited countless urologic cancer patients

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Urology, 1977 - 1978
University of Cincinnati Medical Center/College of MedicineResidency, Urology, 1974 - 1977
TriHealth (Bethesda North Hospital)Internship, Transitional Year, 1973 - 1974
University of Cincinnati College of MedicineClass of 1973

Certifications & Licensure

CO State Medical License 1986 - 2025
CA State Medical License 2019 - 2025
FL State Medical License 2012 - 2016
NM State Medical License 1978 - 1994
OH State Medical License 1974 - 1986
American Board of Urology Urology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2013, 2018
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Men's Health Castle Connolly, 2007
CORE Magazine Castle Connolly, 2006
Join now to see all

Clinical Trials

Medical Therapy of Prostatic Symptoms Start of enrollment: 1995 Dec 01
Completed
Phase 3
Consent for Use of Stored Patient Specimens for Future Testing Start of enrollment: 2002 Feb 13
Recruiting
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT Start of enrollment: 2005 Sep 01
Terminated
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer Start of enrollment: 2006 Aug 01
Active, not recruiting
Phase 3
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil Start of enrollment: 2006 Dec 01
Completed
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2011 Jul 01
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia Start of enrollment: 2014 Aug 01
Completed
Not Applicable
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2014 May 26
Completed
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
Active, not recruiting
Phase 3
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Start of enrollment: 2014 Sep 26
Recruiting
Not Applicable
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Mar 23
Recruiting
Phase 3
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Start of enrollment: 2014 Nov 20
Completed
Phase 3
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer Start of enrollment: 2015 Nov 11
Active, not recruiting
Phase 2
The Treatment of Progressive Early Onset Spinal Deformities: A Multi-Center Outcome Study Start of enrollment: 2008 Oct 01
Completed
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Start of enrollment: 2015 Nov 19
Active, not recruiting
Phase 3
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Start of enrollment: 2015 Dec 22
Active, not recruiting
Phase 2
Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer Start of enrollment: 2015 Dec 01
Completed
Phase 3
ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy Start of enrollment: 2016 May 01
Active, not recruiting
Not Applicable
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
Hafron, J., Crawford, E., Garnick, M.> ;The Journal of Urology. 2024 Mar 1
Editorial Comment.
Garnick, M., Crawford, E.> ;Urology Practice. 2024 Jan 1
Reply by Authors.
Miner, M., Wassersug, R., Rosenberg, M., Walker, L., Fairman, C., Curley, T., Crosby, M., Lin, P., Crawford, E., Garnick, M., Eckel, R., Freedland, S., Pachynski, R., ...> ;Urology Practice. 2024 Jan 1
A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group.
E David Crawford, Marc B Garnick, Robert H Eckel, Martin M Miner, Stephen J Freedland, Russell K Pachynski, Richard J Wassersug, Matthew T Rosenberg, Lauren M Walker, ...> ;Urology Practice. 2024 Jan 1
Editorial Comment.
Juan Javier-DesLoges, Aditya Bagrodia, E David Crawford, Christopher J Kane> ;The Journal of Urology. 2023 Oct 1
1 citations
Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
Sriram Deivasigamani, Srinath Kotamarti, Ardeshir R Rastinehad, Rafael Sanchez Salas, J J M C H de la Rosette, Herbert Lepor, Peter Pinto, Hashim U Ahmed, Inderbir Gil...> ;European Urology. 2023 Dec 1
Editorial Comment.
E David Crawford> ;The Journal of Urology. 2022 Aug 1
Editorial Comment.
E David Crawford> ;The Journal of Urology. 2021 Nov 1
7 citations
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (P...
Herjan J.T. Coelingh Bennink, Jeroen van Moorselaar, E. David Crawford, Erik P.M. Roos, Diederik M. Somford, Ton A. Roeleveld, Tjard D. de Haan, Harm H.E. van Melick, ...> ;European Urology Open Science. 2021 May 6
38 citations
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men
Rianne J. Hendriks, Marloes van der Leest, Bas Israël, Gerjon Hannink, Anglita YantiSetiasti, Erik B. Cornel, Christina A. Hulsbergen-van de Kaa, O. Sjoerd Klaver, J.P...> ;Prostate Cancer and Prostatic Diseases. 2021 May 3
2 citations
Boosting immune response with GM-CSF optimizes primary cryotherapy outcomes in the treatment of prostate cancer: a prospective randomized clinical trial.
Al Barqawi, Rodrigo Rodrigues Pessoa, E. David Crawford, Mohammed Al-Musawi, Tracey MacDermott, Colin O’Donell, Ross M. Kendl> ;Prostate Cancer and Prostatic Diseases. 2021 Feb 8
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical ...
E. David Crawford, Jason Hafron, Scott T. Tagawa, Przemyslaw Twardowski, Richard G. Harris, Judd W. Moul, Thomas E. Keane, Raoul S. Concepcion, Celestia S. Higano, Luc...> ;The Journal of Urology. 2021 Feb 1
EDITORIAL COMMENT.
Nelson N Stone, E David Crawford> ;Urology. 2020 Dec 1
3 citations
Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.
E. David Crawford, Gerald L. Andriole, Stephen J. Freedland, Marc B. Garnick, Leonard G. Gomella, Jonathan Henderson, Celestia Tia Higano, Andrew Karim Kader, Christop...> ;The Canadian Journal of Urology. 2020 Oct 1
11 citations
Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer.
E. David Crawford, Whitney Stanton, Divneet Mandair> ;Cancer Management and Research. 2020 Jul 13
1 citations
69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent.
Eduardo Gonzalez-Ochoa, Haydee Verduzco-Aguirre, E. David Crawford, Maria T Bourlon> ;Oncology. 2020 Apr 10
14 citations
The role of FSH and LH in prostate cancer and cardiometabolic comorbidities.
E. David Crawford, Andrew V. Schally> ;The Canadian Journal of Urology. 2020 Apr 1
6 citations
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clin...
E. David Crawford, Przemyslaw Twardowski, Raoul S. Concepcion, Jason Hafron, Richard G. Harris, Judd W. Moul, Lucio N. Gordan, Daniel P. Petrylak, Stuart Atkinson, Deb...> ;The Journal of Urology. 2020 Apr 1
Editorial Commentary.
E David Crawford> ;Urology Practice. 2020 Mar 1
Assessment of high-grade prostate cancer risk using prostate cancer biomarkers.
Whitney N Stanton, E. David Crawford, Paul Arangua, Francisco G. La Rosa, Adrie van Bokhoven, M. Scott Lucia, Wendy Poage, Alan W. Partin, Paul Maroni, Priya N. Werahera> ;The Canadian Journal of Urology. 2020 Feb 1
Editorial Comment.
E David Crawford> ;The Journal of Urology. 2019 Dec 1
2 citations
67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant Potential.
Luke Bidikov, Paul Maroni, Simon P. Kim, E. David Crawford> ;Oncology. 2019 Sep 20
Reply by Authors.
Nelson N Stone, E David Crawford, Vassilios M Skouteris, Paul Arangua, Panagiotis-Marios Metsinis, M Scott Lucia, Francisco G La Rosa, Priya N Werahera> ;The Journal of Urology. 2019 Aug 1
13 citations
The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transper...
Nelson N. Stone, E. David Crawford, Vassilios Skouteris, Paul Arangua, Panagiotis-Marios Metsinis, M. Scott Lucia, Francisco G. La Rosa, Priya N. Werahera> ;The Journal of Urology. 2019 Jul 8
Editorial Commentary.
E David Crawford> ;Urology Practice. 2019 Jul 1
Join now to see all